Volume | 629,616 |
|
|||||
News | - | ||||||
Day High | 0.8495 | Low High |
|||||
Day Low | 0.80 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
HOOKIPA Pharma Inc | HOOK | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.80 | 0.80 | 0.8495 | 0.819 | 0.81 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
1,233 | 629,616 | US$ 0.814056 | US$ 512,543 | - | 0.41 - 1.27 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
15:21:32 | 1 | US$ 0.8199 | USD |
HOOKIPA Pharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
68M | 83.95M | - | 20.13M | -81.58M | -0.97 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
HOOKIPA Pharma News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical HOOK Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.7666 | 0.909 | 0.76 | 0.8198736 | 666,490 | 0.0524 | 6.84% |
1 Month | 0.81 | 1.05 | 0.73 | 0.8535464 | 804,767 | 0.009 | 1.11% |
3 Months | 0.6831 | 1.05 | 0.68 | 0.8327625 | 881,635 | 0.1359 | 19.89% |
6 Months | 0.584 | 1.13 | 0.54 | 0.818834 | 1,671,533 | 0.235 | 40.24% |
1 Year | 1.19 | 1.27 | 0.41 | 0.7989689 | 1,115,877 | -0.371 | -31.18% |
3 Years | 17.00 | 18.33 | 0.41 | 1.83 | 1,241,036 | -16.18 | -95.18% |
5 Years | 7.79 | 20.00 | 0.41 | 2.36 | 781,659 | -6.97 | -89.49% |
HOOKIPA Pharma Description
HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies. |